Serratus Plane Block After Minimally Invasive Mitral Valve Repair

Phase

N/A

Condition

N/A

Treatment

Continous SAPB (Ropivacain)

institutional standard of care pain medication protocol

Clinical Study ID

NCT05648266

19518181202119

Ages 18-85
All Genders

Study Summary

Patients undergoing minimally invasive mitral valve reconstruction via small thoracotomy are randomized into two groups.

The intervention group receives serratus anterior plane block after minimally invasive mitral-valve reconstruction, following 48h infusion with ropivacaine 2% continually.

The control group receives a placebo pump without infusion. Primary endpoints are perceived pain using a numeric pain rating scale and opioid consumption during the hospital stay.

Eligibility Criteria

Inclusion

Inclusion Criteria:

-Planned minimal invasive mitral valve repair via right anterior thoracotomy

Exclusion

Exclusion Criteria:

Pregenancy
Opioid abuse
Historyof chronic pain
Allergy to local anaesthetics (in this case ropivacain)
Patients who simultaneously participate in another interventional clinical trial,unless the Principal Investigators of the clinical trials give consent by mutualagreement Soft tissue infection in the area of the procedure

Study Design